Wednesday, November 11, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 16, 2026

Smart Home Healthcare Market Outlook 2025-2033: Analysis of Growth Drivers, Constraints, Opportunities, and Trends | Astute Analytica

View original at globenewswire.com
Smart Home Healthcare Market Outlook 2025-2033: Analysis of Growth Drivers, Constraints, Opportunities, and Trends | Astute Analytica Chicago, Jan…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The global smart home healthcare market was valued at US$ 27.46 billion in 2024 and is estimated to surpass a market size of US$ 194.51 billion by 2033 at a CAGR of 24.3% during the forecast period 2025–2033

    80% confidence

  • Testing, screening, and monitoring products captured a commanding 76.90% share of revenue in the smart home healthcare market in 2024

    80% confidence

  • The growth of the smart home healthcare market is strongly influenced by the increasing number of aging individuals who prioritize maintaining independence while managing their health

    80% confidence

  • Approximately 48.9 million households in the United States currently utilize at least one connected health device

    80% confidence

  • The growing prevalence of chronic diseases is a major catalyst driving the expansion of the smart home healthcare market

    80% confidence

  • Global shipment volume of wearable health devices reached 487 million in 2024

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com
Smart Home Healthcare Market Outlook 2025-2033: Analysis of Growth Drivers, Constraints, Opportunities, and Trends | Astute Analytica — Source | Via News | Via News